Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immucell (ICCC) Cash from Financing Activities (2016 - 2025)

Historic Cash from Financing Activities for Immucell (ICCC) over the last 16 years, with Q3 2025 value amounting to -$337689.0.

  • Immucell's Cash from Financing Activities fell 11051.31% to -$337689.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$668918.0, marking a year-over-year decrease of 12772.7%. This contributed to the annual value of $2.9 million for FY2024, which is 6459.54% up from last year.
  • As of Q3 2025, Immucell's Cash from Financing Activities stood at -$337689.0, which was down 11051.31% from -$76448.0 recorded in Q2 2025.
  • Over the past 5 years, Immucell's Cash from Financing Activities peaked at $4.0 million during Q2 2021, and registered a low of -$403647.0 during Q1 2025.
  • In the last 5 years, Immucell's Cash from Financing Activities had a median value of -$176425.0 in 2021 and averaged $463654.8.
  • Its Cash from Financing Activities has fluctuated over the past 5 years, first tumbled by 52891.35% in 2021, then surged by 111438.51% in 2022.
  • Immucell's Cash from Financing Activities (Quarter) stood at -$194905.0 in 2021, then fell by 27.35% to -$248209.0 in 2022, then decreased by 29.5% to -$321433.0 in 2023, then surged by 146.31% to $148866.0 in 2024, then crashed by 326.84% to -$337689.0 in 2025.
  • Its Cash from Financing Activities stands at -$337689.0 for Q3 2025, versus -$76448.0 for Q2 2025 and -$403647.0 for Q1 2025.